Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05742-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Daniel Zechariah Paul Jebanesan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Christian Medical College Vellore-Ranipet Campus, Tamil Nadu, Vellore, 632517, India. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, fms-Like Tyrosine Kinase 3, Arsenic Trioxide, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Department of Science and Technology, Government of Rajasthan.
Abstract (Originalsprache)
De novo acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) have worse treatment outcomes. Arsenic trioxide (ATO) used in the treatment of acute promyelocytic leukemia (APL) has been reported to be effective in degrading the FLT3 protein in AML cell lines and sensitizing non-APL AML patient samples in-vitro. We have previously reported that primary cells from FLT3-ITD mutated AML patients were sensitive to ATO in-vitro compared to other non-M3 AML and molecular/pharmacological inhibition of NF-E2 related factor 2 (NRF2), a master regulator of antioxidant response improved the chemosensitivity to ATO and daunorubicin even in non FLT3-ITD mutated cell lines and primary samples. We examined the effects of molecular/pharmacological suppression of NRF2 on acquired ATO resistance in the FLT3-ITD mutant AML cell line (MV4-11-ATO-R). ATO-R cells showed increased NRF2 expression, nuclear localization, and upregulation of bonafide NRF2 targets. Molecular inhibition of NRF2 in this resistant cell line improved ATO sensitivity in vitro. Digoxin treatment lowered p-AKT expression, abrogating nuclear NRF2 localization and sensitizing cells to ATO. However, digoxin and ATO did not sensitize non-ITD AML cell line THP1 with high NRF2 expression. Digoxin decreased leukemic burden and prolonged survival in MV4-11 ATO-R xenograft mice. We establish that altering NRF2 expression may reverse acquired ATO resistance in FLT3-ITD AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Christian Medical College Vellore-Ranipet Campus, Tamil Nadu, Vellore, 632517, India.
- Manipal Academy of Higher Education, Manipal, India.
- Department of Integrative Biology, School of BioSciences and Technology, Vellore Institute of Technology, Vellore, India.
- Adjunct Scientist, Centre for Stem Cell Research, A Unit of InStem Bengaluru, CMC Campus, Vellore, India.
- Department of Hematology, Christian Medical College Vellore-Ranipet Campus, Tamil Nadu, Vellore, 632517, India. bpoonkuzhali@cmcvellore.ac.in.
Förderung
- Department of Science and Technology, Government of Rajasthan
Zitieren
APA
Jebanesan, D. Z. P., Illangeswaran, R. S. S., Rajamani, B. M., Vidhyadharan, R. T., Das, S., Bijukumar, N. K., Balakrishnan, B., Mathews, V., Velayudhan, S. R., & Balasubramanian, P. (2024). Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05742-8
Vancouver
Jebanesan DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, Das S, Bijukumar NK, et al. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-05742-8
BibTeX
@article{Jebanesan2024,
author = {Jebanesan, Daniel Zechariah Paul and Illangeswaran, Raveen Stephen Stallon and Rajamani, Bharathi M and Vidhyadharan, Rakhi Thalayattu and Das, Saswati and Bijukumar, Nayanthara K and Balakrishnan, Balaji and Mathews, Vikram and Velayudhan, Shaji R and Balasubramanian, Poonkuzhali},
title = {Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05742-8}
}
EUVIMED